Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium.
Terbach N
,
Shah R
,
Kelemen R
,
Klein PS
,
Gordienko D
,
Brown NA
,
Wilkinson CJ
,
Williams RS
.
???displayArticle.abstract???
Valproic acid (VPA) is the most highly prescribed epilepsy treatment worldwide and is also used to prevent bipolar disorder and migraine. Surprisingly, very little is known about its mechanisms of cellular uptake. Here, we employ a range of cellular, molecular and genetic approaches to characterize VPA uptake using a simple biomedical model, Dictyostelium discoideum. We show that VPA is taken up against an electrochemical gradient in a dose-dependent manner. Transport is protein-mediated, dependent on pH and the proton gradient and shows strong substrate structure specificity. Using a genetic screen, we identified a protein homologous to a mammalian solute carrier family 4 (SLC4) bicarbonate transporter that we show is involved in VPA uptake. Pharmacological and genetic ablation of this protein reduces the uptake of VPA and partially protects against VPA-dependent developmental effects, and extracellular bicarbonate competes for VPA uptake in Dictyostelium. We further show that this uptake mechanism is likely to be conserved in both zebrafish (Danio rerio) and Xenopus laevis model systems. These results implicate, for the first time, an uptake mechanism for VPA through SLC4-catalysed activity.
Adkison,
Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter.
1996, Pubmed
Adkison,
Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter.
1996,
Pubmed
Alper,
How pH regulates a pH regulator: a regulatory hot spot in the N-terminal cytoplasmic domain of the AE2 anion exchanger.
2002,
Pubmed
Baltes,
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays.
2007,
Pubmed
Berridge,
Neural and developmental actions of lithium: a unifying hypothesis.
1989,
Pubmed
Björnsson,
Hepatotoxicity associated with antiepileptic drugs.
2008,
Pubmed
Boeckeler,
The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum.
2006,
Pubmed
Bokelmann,
Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins.
2008,
Pubmed
Brouwer,
Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
1993,
Pubmed
Calabresi,
Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms.
2007,
Pubmed
Chang,
Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers.
2001,
Pubmed
Chapman,
Mechanism of anticonvulsant action of valproate.
1982,
Pubmed
Chen,
The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
1999,
Pubmed
Deuticke,
Discrimination of three parallel pathways of lactate transport in the human erythrocyte membrane by inhibitors and kinetic properties.
1982,
Pubmed
Eickholt,
Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
2005,
Pubmed
Emrich,
Therapeutic effect of valproate in mania.
1981,
Pubmed
Faix,
A rapid and efficient method to generate multiple gene disruptions in Dictyostelium discoideum using a single selectable marker and the Cre-loxP system.
2004,
Pubmed
Fischer,
Transport of valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specificity.
2008,
Pubmed
Gibbs,
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
2004,
Pubmed
Gögelein,
Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancreas.
1990,
Pubmed
Gonçalves,
Modulation of butyrate transport in Caco-2 cells.
2009,
Pubmed
Gurvich,
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo.
2005,
Pubmed
,
Xenbase
Izumi,
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy.
2003,
Pubmed
Jonathan Ryves,
GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.
2005,
Pubmed
Kessel,
Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer.
2001,
Pubmed
Koszela-Piotrowska,
Stilbene derivatives inhibit the activity of the inner mitochondrial membrane chloride channels.
2007,
Pubmed
Lecona,
Kinetic analysis of butyrate transport in human colon adenocarcinoma cells reveals two different carrier-mediated mechanisms.
2008,
Pubmed
Liu,
Altered expression of the 100 kDa subunit of the Dictyostelium vacuolar proton pump impairs enzyme assembly, endocytic function and cytosolic pH regulation.
2002,
Pubmed
Löscher,
Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.
1989,
Pubmed
McNiff,
Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance.
1994,
Pubmed
Mesdjian,
Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat.
1982,
Pubmed
MEUNIER,
[Pharmacodynamic properties of N-dipropylacetic acid].
1963,
Pubmed
Nakamura,
Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles.
2002,
Pubmed
Ornoy,
Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.
2006,
Pubmed
Ortwein,
Band 3, the anion exchanger of the erythrocyte membrane, is also a flippase.
1994,
Pubmed
Pawolleck,
Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells.
2009,
Pubmed
Phiel,
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
2001,
Pubmed
,
Xenbase
Pushkin,
SLC4 base (HCO3 -, CO3 2-) transporters: classification, function, structure, genetic diseases, and knockout models.
2006,
Pubmed
Romero,
The SLC4 family of HCO 3 - transporters.
2004,
Pubmed
Siafaka-Kapadai,
Incorporation of [3H]valproic acid into lipids in GT1-7 neurons.
1998,
Pubmed
Soll,
Stationary phase and the cell cycle of Dictyostelium discoideum in liquid nutrient medium.
1976,
Pubmed
Tamai,
Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.
1995,
Pubmed
,
Xenbase
Terbach,
Structure-function studies for the panacea, valproic acid.
2009,
Pubmed
Tian,
Valproic acid inhibits the depolarizing rectification in neurons of rat amygdala.
1994,
Pubmed
Utoguchi,
Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line.
2000,
Pubmed
Williams,
A common mechanism of action for three mood-stabilizing drugs.
2002,
Pubmed
Williams,
Towards a molecular understanding of human diseases using Dictyostelium discoideum.
2006,
Pubmed
Williams,
Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate.
1999,
Pubmed
Yabuuchi,
Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter.
1998,
Pubmed
